On the limits of enhancement in human gene transfer: Drawing the line

Journal of Medicine and Philosophy

Volumn 22, Issue 1, 1997, Pages 43-53

  Torres, Juan Manuel ^a  

^a UNIVERSIDAD NACIONAL DEL SUR   (Argentina)

Author keywords

Gene medicine; Human gene transfer; Multidrug resistance protocol; Trait enhancement

Indexed keywords

ANALYTICAL APPROACH; ARTICLE; BIOETHICS; DECLARATION OF INUYAMA; GENE THERAPY; GENE TRANSFER; GENETIC ENGINEERING; GENETIC ENHANCEMENT; GENETICS; GENETICS AND REPRODUCTION; HUMAN; HUMAN CHARACTERISTIC; MORALITY; MULTIDRUG RESISTANCE; QUALITY OF LIFE; RISK ASSESSMENT; SOCIAL PSYCHOLOGY; STANDARD;

ANALYTICAL APPROACH; DECLARATION OF INUYAMA; GENETICS AND REPRODUCTION;

BIOETHICS; DRUG RESISTANCE, MULTIPLE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC ENGINEERING; GENETIC ENHANCEMENT; GENETIC RESEARCH; HUMAN CHARACTERISTICS; HUMANS; MORALS; QUALITY OF LIFE; RISK ASSESSMENT; SOCIAL VALUES;

EID: 0031062806     PISSN: 03605310     EISSN: None     Source Type: Journal    
DOI: 10.1093/jmp/22.1.43     Document Type: Article

References (19)

1. Anderson, F.: 1987, 'Human gene therapy: Scientific and ethical considerations,' in R. Chadwick (ed.) Ethics, Reproduction and Genetic Control, Croom Helm, New York, pp. 160-161.
2. Anderson, F.: 1992, 'Uses and abuses in human gene transfer,' Human Gene Therapy, 3, pp. 1-2.
3. Aquinas Thomas: c. 1250, De Ente et Essentia.
4. Fletcher, J.: 1990, 'Evolution of ethical debate about human gene therapy,' Human Gene Therapy, 1, pp. 55-68.
5. Germann, U., Pastan, I. and Gottesman, M.: 1993, 'P-glycoprotein: Mediators of multidrug resistance,' Seminars in Cell Biology, 4, pp. 63-76.
6. Gottesman, M. and Pastman, I.: 1991, 'The multidrug resistance (MDR1) gene as selectable marker in gene therapy,' in O. Cohen-Haguenauer and M. Boiron (eds.), Human Gene Transfer, Colloque INSERM/John Libbey Eurotext Ltd., vol. 219, pp. 185-192.
7. Hesdorffer, Ch., Antman, K., Bank, A. Fetell, M., Mears, G. and Begg, M.: 1994, 'Clinical protocol: Human MDR gene transfer in patients with advanced cancer,' Human Gene Therapy, 5, pp. 1151-1160.
8. Juengst, E.: 1990, 'The NIH "Points to Consider" and the limits of human gene therapy,' Human Gene Therapy, 1, pp. 425-433.
9. Juengst, E.: 1992, 'Germ-line gene therapy: Back to basics,' Human Gene Therapy, 3, pp. 45-49.
10. Larry J. and Burk, K.: 1991, Gene Therapy, Elsevier Science Publishing, New York.
11. Mitani, K. and Caskey, T.: 1993, 'Delivering therapeutic genes - matching approach and application,' Trends in Biotechnology, 11, pp. 162-166.
12. Neel, J.: 1993, 'Germ-line gene therapy: Another view,' Human Gene Therapy, 4, pp. 127-128.
13. Porter, J.: 1990, 'What is morally distinctive about genetic engineering,' Human Gene Therapy, 1, pp. 419-424.
14. Royal Comission on New Reproductive Technologies, Canada, Final Report: 1994, 'Proceed with care,' in Human Gene Therapy, 5, pp. 603-614.
15. Sikola, K.: 1993, 'Gene therapy for cancer,' Trends in Biotechnology, 11, pp. 197-201.
16. Tauer, C.: 1990, 'Does human gene therapy raise new ethical questions?' Human Gene Therapy, 1, pp. 411-418.
17. The Council for International Organizations of Medical Sciences (CIOMS): 1990, The Declaration of Inuyama, XXIVth. Conference, Tokyo and Inuyama.
18. Torres, J.M.: 1995, 'The importance of accurate terminology in the field of human gene transfer,' Human Gene Therapy, 6, pp. 133-135.
19. Wivel, N.: 1993 'Regulatory considerations for gene-therapy strategies and products,' Trends in Biotechnology, 11, pp. 189-192.